HUTCHMED begins a Phase Ia trial for HMPL-A830, a therapy targeting KRAS in advanced tumors, in China.Quiver AI SummaryHUTCHMED (China) Limited has launched the Phase Ia portion of a global clinical trial for its innovative drug candidate HMPL-A830, aimed at treating patients with unresectable, advanced, or metastatic solid tumors. The trial commenced in China, where the first patient was dosed on September 24, 2026. HMPL-A830 is a first-in-classRead More
